Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...
As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents. The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and ...
The additional funding will be used by Mentor’s K9 operations for training, pet supplies, protective vests, health care and ...
The New York Jets defender is dealing with an Achilles injury. He’s sidelined for the long haul, but he’s still putting in the work. Alongside his girlfriend, Johnson has posted a video update of him ...
Mario Draghi's report on European competitiveness highlights key challenges and offers a comprehensive plan for revitalizing ...
Axios on MSN3d
North Carolina: Trump's emerging Achilles HeelFormer President Trump's campaign is alarmed by the idea that North Carolina Lt. Gov. Mark Robinson's political baggage and ...
American depositary receipts of Achilles Therapeutics rose 32% after the company disclosed cost-cutting measures as part of a strategic update. ADRs were trading around 94 cents. ADRs are up about 12% ...
Shares of Achilles Therapeutics plc (NASDAQ: ACHL) are surging following a major strategic announcement from the company. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback